Concurrent paclitaxel and radiation therapy for the treatment of cutaneous angiosarcoma
Autor: | Imran Zoberi, V. L. Keedy, Jeff M. Michalski, John S.A. Chrisinger, Brian A. Van Tine, Elizabeth J. Davis, Matthew B. Spraker, Emily Merfeld, Amit Roy, Peter Oppelt, Prashant Gabani |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
genetic structures Paclitaxel medicine.medical_treatment Urology R895-920 RT radiotherapy 030218 nuclear medicine & medical imaging OS overall survival 03 medical and health sciences chemistry.chemical_compound Medical physics. Medical radiology. Nuclear medicine 0302 clinical medicine Angiosarcoma Medicine Chemotherapy DC distant control Radiology Nuclear Medicine and imaging cardiovascular diseases Original Research Article Progression-free survival Non-CRT other modalities RC254-282 business.industry CRT paclitaxel-based chemoradiation Neoplasms. Tumors. Oncology. Including cancer and carcinogens equipment and supplies PFS progression-free survival Radiation therapy Regimen Oncology chemistry 030220 oncology & carcinogenesis Cohort cardiovascular system Concurrent chemoradiation LC local control business Chemoradiotherapy circulatory and respiratory physiology |
Zdroj: | Clinical and Translational Radiation Oncology, Vol 27, Iss, Pp 114-120 (2021) Clinical and Translational Radiation Oncology |
ISSN: | 2405-6308 |
Popis: | Highlights • Cutaneous angiosarcoma has poor outcomes with no standardized treatment regimen. • Paclitaxel-based chemoRT (CRT) was compared to other therapies at two US institutions. • Similar oncologic outcomes and improved survival with paclitaxel CRT. • Paclitaxel CRT + surgery provided best oncologic outcomes and survival. • Paclitaxel CRT + surgery regimen now being studied in a prospective phase II trial. Introduction We compared clinical outcomes in patients with cutaneous angiosarcoma receiving concurrent paclitaxel-based chemoradiotherapy (CRT) vs. other modalities (Non-CRT). Materials and methods Patients with non-metastatic cutaneous angiosarcoma diagnosed from 1998 to 2018 at two institutions were identified. In the CRT cohort, paclitaxel 80 mg/m2 weekly was given for up to 12 weeks and patients received radiotherapy (RT) during the final 6 weeks of chemotherapy. The RT dose was 50–50.4 Gy delivered in 1.8–2 Gy per fraction with an optional post-operative boost of 10–16 Gy. Kaplan-Meier and log-rank statistics were used to compare the outcomes between the two groups. P 60 years (100% vs. 60%, p 5 cm (68.2% vs 54.3%, p = 0.023). The median follow-up was 25.8 (1.5–155.2) months. There was no significant difference in 2-year local control (LC), distant control (DC), or progression-free survival (PFS) between the two groups. The 2-year overall survival (OS) was significantly higher for the CRT cohort (94.1% vs. 71.6%, p = 0.033). Amongst the subset of patients in the CRT cohort who received trimodality therapy, the 2-year LC, DC, PFS, and OS was 68.6%, 100%, 68.6%, and 100%, respectively. Conclusion The use of concurrent paclitaxel CRT demonstrates promising outcomes. Given these results, we are currently evaluating the safety and efficacy of this regimen in prospective, phase 2 trial (NCT 03921008). |
Databáze: | OpenAIRE |
Externí odkaz: |